OTX-TIC is an injectable intracameral prostaglandin analog (PGA) implant undergoing evaluation as a treatment for elevated intraocular pressure targeting patients with moderate to severe open-angle glaucoma or ocular hypertension.
OTX-TIC at 3 days in-vivo (canine); able to be visualized due to fluorescein conjugation
OTX-TIC resides in
OTX-TIC is designed to be a bioresorbable implant containing micronized travoprost that is injected into the anterior chamber of the eye, with a target duration of drug delivery of three to four months. Preclinical studies in beagles have demonstrated sustained intraocular pressure lowering and maintenance of drug levels in the aqueous humor.
Caution: NEW DRUG – OTX-TIC is currently undergoing clinical evaluation in the United States and is limited by United States law to investigational use only. This product has not been approved by the FDA as safe or effective.
“OTX-TIC may provide a transformative modality with the potential to change the current standard of care.”
-Amar Sawhney, Ph.D., Executive Chairman
Injection of OTX-TIC implant in the anterior chamber of the eye.
Implant drops down and resides in the iridocorneal angle.